UNAIDS Executive Director Winnie Byanyima speaks during the Launch of HIV Prevention Project in Johannesburg, South Africa, ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Despite Uganda's steady progress in reducing HIV infections and AIDS-related deaths, men remain disproportionately affected due to low uptake of antiretroviral treatment (ARVs), the Uganda AIDS ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...

Ruanne Barnabas grew up in Durban, South Africa, during a time of “deep inequity in health, opportunity, and justice”.

Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...